Pemphigus diseases (PDs) and mucous membrane pemphigoid (MMP) are a group of immune-mediated mucocutaneous disorders clinically characterized by the formation of blisters, erosions and ulcers. The skin and mucous membranes are predominantly affected, with the oropharyngeal mucosa as the initially involved site. Ocular involvement is also a frequent feature of these diseases. Because of the considerable overlap in their clinical presentations, the diagnosis of PDs vs. MMP can be challenging. A recognition of their specific immunological and histopathologic features is crucial in the differential diagnosis. Treatment modalities include systemically administered corticosteroids, steroid-sparing immunosuppressive agents, and biologic therapies (rituximab, intravenous immunoglobulins, and anti-tumor necrosis factor agents). Topical, oral, conjunctival, or intralesional corticosteroids as well as anti-inflammatory drugs and antibiotics are prescribed as needed.

Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy / Buonavoglia, Alessio; Leone, Patrizia; Dammacco, Rosanna; Di Lernia, Giuseppe; Petruzzi, Massimo; Bonamonte, Domenico; Vacca, Angelo; Racanelli, Vito; Dammacco, Franco. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 18:4(2019), pp. 349-358. [10.1016/j.autrev.2019.02.005]

Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy

Racanelli, Vito;
2019-01-01

Abstract

Pemphigus diseases (PDs) and mucous membrane pemphigoid (MMP) are a group of immune-mediated mucocutaneous disorders clinically characterized by the formation of blisters, erosions and ulcers. The skin and mucous membranes are predominantly affected, with the oropharyngeal mucosa as the initially involved site. Ocular involvement is also a frequent feature of these diseases. Because of the considerable overlap in their clinical presentations, the diagnosis of PDs vs. MMP can be challenging. A recognition of their specific immunological and histopathologic features is crucial in the differential diagnosis. Treatment modalities include systemically administered corticosteroids, steroid-sparing immunosuppressive agents, and biologic therapies (rituximab, intravenous immunoglobulins, and anti-tumor necrosis factor agents). Topical, oral, conjunctival, or intralesional corticosteroids as well as anti-inflammatory drugs and antibiotics are prescribed as needed.
2019
4
Buonavoglia, Alessio; Leone, Patrizia; Dammacco, Rosanna; Di Lernia, Giuseppe; Petruzzi, Massimo; Bonamonte, Domenico; Vacca, Angelo; Racanelli, Vito; Dammacco, Franco
Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy / Buonavoglia, Alessio; Leone, Patrizia; Dammacco, Rosanna; Di Lernia, Giuseppe; Petruzzi, Massimo; Bonamonte, Domenico; Vacca, Angelo; Racanelli, Vito; Dammacco, Franco. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 18:4(2019), pp. 349-358. [10.1016/j.autrev.2019.02.005]
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S156899721930031X-main.pdf

Solo gestori archivio

Descrizione: Article in press
Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF   Visualizza/Apri
11586-226605.pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/387019
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 66
social impact